News Releases

Company
AgeX Therapeutics

AgeX Therapeutics to collaborate with University of California, Irvine on Neural Stem Cell Research Program

AgeX, a Juvenescence partner, announced a research collaboration with the UC Irvine using AgeX’s PureStem® to derive neural stem cells with the goal of developing cellular therapies to treat neurological disorders and diseases with no cure.

February 3, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

January 29, 2020

Read More
Insilico Medicine

Insilico Enters Into Research Collaboration with Pfizer Inc.

Insilico Medicine, a Juvenescence partner, enters into research collaboration with Pfizer Inc. to utilize Insilico’s machine learning technology to identify evidence for potential therapeutic targets implicated in a variety of diseases.

January 14, 2020

Read More
Juvenescence

Extension of NetraMark’s NetraPharma Collaboration with Juvenescence

NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.

December 10, 2019

Read More
AgeX Therapeutics

AgeX Therapeutics Issues Year-End Letter to Shareholders

At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.

December 9, 2019

Read More
AgeX Therapeutics

AgeX Therapeutics and Juvenescence Publish Engineering Strategies for Universal Cells

AgeX Therapeutics, a biotechnology company, and Juvenescence, a biotech longevity company, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine.

October 30, 2019

Read More
LyGenesis

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of Liver Regeneration Technology

LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision Fund.

October 21, 2019

Read More
Insilico Medicine

Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners

Insilico Medicine, a next generation AI technology and Juvenescence partner, completes $37 million Series B funding that will be used to commercialize the validated generative chemistry and target identification technology.

September 10, 2019

Read More
Insilico Medicine

Insilico Medicine Develops and Validates Powerful AI System To Transform Drug Discovery

Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days.

September 2, 2019

Read More
AgeX Therapeutics

AgeX Therapeutics publishes Theoretical Basis of Human Cell-Age Reversal in the Journal of Regenerative Medicine

AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.

August 28, 2019

Read More
Juvenescence

Juvenescence closes $100 Million Series B Round

Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.

August 19, 2019

Read More
Juvenescence

Juvenescence appoints Colin Watts as CEO of Juvenescence Life

Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. Driving Human longevity and quality of life.

July 11, 2019

Read More
Juvenescence

Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments

Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.

May 28, 2019

Read More
Juvenescence

Juvenescence Announces the Appointment of David Ellam as Chief Financial Officer

Juvenescence announces that David Ellam has joined its Executive Management Team as Chief Financial Officer.

April 24, 2019

Read More
Juvenescence

Juvenescence Capitalizes BYOMass

Juvenescence is pleased to announce its latest equity investment in BYOMass, a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.

March 27, 2019

Read More
Contact Us
We are here to help answer any questions you might have.